Clinical trial
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced…
NCT00274781 · The Cleveland Clinic, Other · Completed
Key facts
| NCT number | NCT00274781 |
|---|---|
| Title | Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes |
| Official title | A Phase II Trial of Combination Therapy With Arsenic Trioxide (Trisenox) and Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Adult Patients With Advanced Myelodysplastic Syndrome |
| Lead sponsor | The Cleveland Clinic, Other |
| Collaborators | University of Michigan National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myelodysplastic Syndromes |
| Intervention type | Drug |
| Interventions | arsenic trioxide, gemtuzumab ozogamicin |
| Enrollment | 30 |
| Start date | Feb 1, 2004 |
| Primary completion | Dec 1, 2008 |
| Completion | Nov 1, 2010 |
| First posted | Jan 11, 2006 |
| Last update posted | Jul 10, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: